Dr. Su is a famous medical oncologist in Taiwan, focusing on treating genitourinary, colorectal cancer and soft tissue sarcoma. He is an Associate Professor, and currently holds a position as the Deputy Director of Hematology Oncology and Clinical Trial Center at Kaohsiung Chang Gung Memorial Hospital. As a principal investigator, he participated in many pivotal phase III clinical trials (RANGE, IMVigor-130, KEYNOTE-361, DANUBE, etc.) with good execution quality. Acting as a modern clinical oncologist, he is dedicated to solving clinical problems and finds the solution through novel genomic research. His research interests are focused on multi-omics analysis of cancer biology and cancer immunology in the field of genitourinary and colorectal cancer. His works on determining prognostic models of metastatic urothelial carcinoma had fruitful results yielding 7 published articles in PLoS One, Sci Rep. and J of Cancer (all as major authors). In addition, he published several articles regarding the biologic roles of molecular marker (galectin-1, SPARCL1) in urothelial carcinoma. Recently, he is interested in cancer immunotherapy and is trying to find out predictive biomarkers of immune checkpoint inhibitor in urothelial carcinoma.